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ABSTRACT: 
Cancer  hallmarks  include  evading  apoptosis,  limitless  replicative  potential,  sustained 
angiogenesis, tissue invasion and metastasis. Cancer cells undergo metabolic reprogramming and 
inevitably take advantage of glycolysis to meet the increased metabolic demand: rapid energy 
generation and macromolecular synthesis. Resveratrol, a polyphenolic phytoalexin, is known to 
exhibit pleiotropic anti-cancer effects most of which are linked to metabolic reprogramming in 
cancer cells. This review summarizes various anti-cancer effects of resveratrol in the context of 
cancer hallmarks in relation to metabolic reprogramming.  
 
 
INTRODUCTION: 
Tumor cells rely on glycolysis rather than oxidative phosphorylation for ATP production even in 
the presence of oxygen, this is called the Warburg effect. Since the proposal of metabolic shift 
from aerobic respiration to aerobic glycolysis in neoplastic cells [1], supporting evidence has 
been accumulated in many types of cancers [2]. The Warburg effect in the context of concerted 
changes  in  energy  metabolism  including  mitochondrial  function  for  carcinogenesis  is  often 
referred to as metabolic reprogramming [3]. Although most of the exact molecular mechanisms 
underlying  metabolic  reprogramming  are  needed  to  be  elucidated,  many  anti-cancer  agents 
targeting the metabolic reprogramming are under investigation in the preclinical and clinical 
setting [4].  Functional Foods in Health and Disease 2013; 3(8):332-343 
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Among the agents is a naturally occurring compound, phytochemicals, which comprise 
different  classes  such  as  terpenoids,  glucosinolates,  anthraquinones,  and  polyphenolics  [5]. 
Resveratrol (3, 5, 4'-trihydroxy-trans-stilbene), a biologically potent member of polyphenolics, 
was known as one of phytoalexins [6]. Tremendous interest in resveratrol of earlier days was 
mainly due to the epidemiological finding of so-called “French paradox”, i.e., despite high fat 
intake, mortality from coronary heart disease of people who regularly drink wine is low [7]. 
Parallel to the anti-cardiovascular effect, anti-cancer effect of resveratrol has been extensively 
studied for the past several years. An enormous amount of evidence has proposed many different 
mechanisms  associated  with  resveratrol, including anti-oxidant and anti-mutagenic properties 
[8]. Despite the fact that a lot of anti-cancer mechanisms of resveratrol are still largely obscure, 
the  pleiotropic  nature  of  its  anti-cancer  effect  is  noteworthy  (figure  1).  This  review,  herein, 
summarizes  various  anti-cancer  effects  of  resveratrol  in  the  context  of  cancer  hallmarks  in 
relation to metabolic reprogramming.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  1.  Possible  targets  of  resveratrol  and  proposed  roles  of  cancer  metabolism  in  the 
expression of cancer hallmarks. The hallmarks concern the cancer cells themselves except apoptosis, which 
concerns  neighboring  normal  cells.  The  glucose  uptake  rates  of  cancer  cells  are  much  higher  than  those  of 
neighboring cells, leading to apoptosis of the latter. High glycolytic fluxes allow rapid processing of glucose into 
lactate, which, together with protons, induces apoptosis in normal cells, blocks immune cell function and guides 
tissue invasion by tumors. Hypoxia existing in tumors is not only responsible for tumor resistance, but also supports 
angiogenesis  and  metastasis  through  HIF-1  activity.  Abbreviations:  AcCoA;  EMT,  epithelial-mesenchymal 
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transition;  HIF-1,  hypoxia  inducible  factor-1;  ʱ-KG,  ʱ-ketoglutarate;  MDR,  multi-drug  resistance;  TCA, 
tricarboxylic  acid  cycle;VEGF,  vascular  endothelial  growth  factor.  Adapted  from  Ferreira  et  al.  (2012)  under 
permission from nature publishing group. 
 
Anti-cancer mechanisms of resveratrol against hallmarks of Cancer - Inhibiting three key 
glycolytic  enzymes:  hexokinase,  phosphofructokinase,  and  pyruvate  kinase:  Hexokinase 
(HK) catalyzes the essentially irreversible first step of the glycolytic pathway where glucose is 
phosphorylated to glucose-6-phosphate. Among four isoforms of HK, HK II is known to be 
overexpressed in most neoplastic cells where it contributes to the proliferation and survival of 
tumor  cells  through  enhancing  aerobic  glycolysis  [9].  There  is  no  evidence  suggesting  that 
resveratrol directly inhibits the enhanced activity of HK II in tumor cells. However, growing 
evidence  supports  indirect  HK  II  inhibition  by  resveratrol  through  the  inhibitory  effect  of 
resveratrol  on  receptor  tyrosine  kinase  (RTK)/phosphoinositide-3-kinase 
(PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway in many types of cancer cells 
[10, 11]. Resveratrol-induced HK II inhibition also seems to be mediated through the inhibition 
of  hypoxia-inducible  factor-1ʱ  (HIF-1ʱ),  a  transcription  factor  that  reprograms  cancer  cell 
metabolism [12]. HIF-1ʱ overexpression is observed in a wide array of human cancers, which is 
known  to  be  substantially  responsible  for  the  higher  rate  of  glycolysis  by  the  induction  of 
glycolytic enzymes including HK II [13, 14]. Zhang et al. indicated that resveratrol treatment 
down-regulated the expression of HIF-1ʱ proteins in human nasopharyngeal carcinoma cells 
[15].  
The enzyme 6-phosphofructo-1-kinase (PFK1) is another critical glycolytic enzyme which 
catalyzes the transfer of a phosphate from ATP to fructose-6-phosphate to produce fructose-1,6-
bisphosphate and adenosine diphosphate (ADP) [16]. The expression of PFK-L isoform was 
shown to correlate directly with aggressiveness and glycolytic efficiency, i.e., lactate produced 
per glucose consumed, in breast cancer cell lines [17]. Moreover, PFK1 inhibition can lead to 
cell death in human breast cancer cell lines, which suggests that PFK1 might play a critical role 
in cell fate decision in these cell lines [18]. Gomez et al. demonstrated that resveratrol decreased 
viability, glucose consumption and ATP content in human breast cancer cell line MCF-7, and 
these effects were correlated with PFK1 inhibition by resveratrol [16]. They also reported that 
resveratrol directly inhibited purified PFK1 mainly through the dissociation of the PFK1 from 
fully active tetramers into less active dimers. 
Among the enzymes that undergo changes during tumor formation is pyruvate kinase (PK). 
PK  catalyzes  the  dephosphorylation  of  phosphoenolpyruvate  to  pyruvate  and  yields  one 
molecule of ATP [12]. In tumor cells, the glycolytic PK isoenzyme M2 (PKM2) determines 
whether  glucose  is  converted  to  lactate  for  regeneration  of  energy  (active  tetrameric  form, 
Warburg effect) or used for the synthesis of cell building blocks (nearly inactive dimeric form) 
[19]. Because of the lower glycolytic activity of PKM2 than the constitutively active isoform, 
PKM1, cancer cells are likely to accumulate several glycolytic intermediates for macromolecular 
biosynthesis,  for  example,  ribose-5-phosphate  using  pentose  phosphate  pathway  (PPP)  [20]. 
mTOR  up-regulates  PKM2  via  HIF-1ʱ,  while  PKM2  conversely  promotes  transcriptional 
activity of HIF-1ʱ, activating glycolysis at several levels and compensating the low glycolytic 
activity of PKM2 [21]. Resveratrol was shown to down-regulate PKM2 expression by inhibiting Functional Foods in Health and Disease 2013; 3(8):332-343 
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mTOR  signaling. Down-regulation  of PKM2 expression results  in  the suppression of cancer 
metabolism.  Decreased  glucose  uptake  and  lactate  production,  and  reduced  anabolism  were 
demonstrated in various cancer cell lines [20]. An over-expression of PKM2 abolished the effects 
of  resveratrol,  emphasizing  the  role  of  PKM2  down-regulation  as  a  critical  function  of 
resveratrol.    
 
Enhancing apoptotic cell death: Cancer cells are characterized by uncontrolled proliferation 
and  defective  apoptosis  which  contributes  to  chemotherapy  resistance  [22].  Changes  of 
components  of  apoptotic  machinery  on  mitochondrial  membrane  were  suggested  to  be 
underlying mechanism of the defective apoptosis in cancer cells [9].  
In addition to providing the precursor for glycolysis and biosynthesis of key metabolites, 
mitochondrial  HK  II  may  provide  one  link  between  inhibition  of  apoptosis  and  metabolic 
reprogramming in cancer cells through the interaction with the voltage-dependent anion channel 
(VDAC)  on  outer  mitochondrial  membrane  (OMM)  [22].  Partly  due  to  the  increased 
translocation of HK II to OMM by the constitutively activated Akt in cancer cells, the HK II-
VDAC interaction was increased in cancer cells compared with normal cells. Furthermore, HK II 
was shown to bind more tightly to VDAC on OMM in tumor cells than in normal cells [23]. In 
addition to HK II-VDAC interaction, another critical regulation of the cellular apoptosis is the 
balance  between  pro-  and  anti-apoptotic  proteins  [24].  HK  II  may  compete  with  the  anti-
apoptotic protein Bcl-XL for VDAC binding site. Thus, HK II binding to VDAC releases Bcl-XL 
from VDAC and facilitates binding of Bcl-XL to Bax, which prevents Bax-Bax oligomerization 
or  Bax-Bak  interaction.  However,  HK  II  detachment  from  VDAC,  for  example,  through 
phosphorylation  of  VDAC  by  glycogen  synthase  kinase  3β,  promotes  binding  of  Bcl-XL  to 
VDAC, leaving Bax free from Bcl-XL. Free Bax interacts with Bak/Bax to form pore structures 
for the release of cytochrome c, the commitment step of mitochondria-mediated apoptosis [25].  
Resveratrol activity might reduce the translocation of HK II to OMM, thus preventing HK 
II-VDAC interaction and facilitating the detachment of HK II from VDAC via the inhibition of 
RTK/PI3K/AKT/mTOR  pathway  [10,  11]. The  detachment  of  HK  II  from  the  mitochondria 
might sensitize the mitochondria to the cisplatin-induced cell damage, leading to much enhanced 
apoptotic  cell  death  [26].  Resveratrol  was  reported  to  induce  apoptosis  dominantly  via  the 
activation of Bak- but not Bax-mediated intrinsic pathway in human lung adenocarcinoma cells 
[27]. However, the growth-inhibitory and pro-apoptotic effects of piceatannol, a hydroxylated 
analog of resveratrol, were shown to be mediated through up-regulation of Bid, Bax. Bik, Bok, 
Fas: P21(WAF1), down-regulation of Bcl-xL; Bcl-2, clAP, activation of caspases (-3, -7,- 8, -9), 
loss of mitochondrial potential, and release of cytochrome c in a wide variety of tumor cells [28]. 
More recently, dimethylated analog of  resveratrol,  pterostilbene, was  demonstrated to  down-
regulate  the  anti-apoptotic  proteins  Bcl-XL  and  Mcl-1,  leading  to  the  up-regulation  of 
mitochondrial apoptosis pathway-related proteins including Bax, Bak, cytochrome c, and cleaved 
caspase 3 in osteosarcoma cells [29].  
There is another mechanism of resveratrol enhancing apoptosis of cancer cells. Low pH, 
caused by the accumulation of lactate due to up-regulated glycolysis in cancer cells, was shown 
to induce base rotation in DNA especially copper bound N7 guanine that can lead to exposure of 
the  metal  ion.  Resveratrol  seems  to  easily  attack  exposed  copper,  reducing  it  and  thereby Functional Foods in Health and Disease 2013; 3(8):332-343 
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generating reactive oxygen species (ROS), leading to oxidative DNA damage [30]. These results 
suggest that resveratrol could be an effective treatment for tumors that are hypoxic and have low 
pH microenvironment. 
Death receptor pathway, also known as the extrinsic pathway, is another apoptotic pathway 
through which the pro-apoptotic effect of resveratrol might be exhibited. Briefly, resveratrol can 
up-regulate  the  expression  of  death  receptor  ligands  such  as  FasL  and  CD95L  directly  or 
indirectly through activating p53, leading to increase and relocalization of death receptors in 
lipid microdomains and forming the death-inducing signaling complex (DISC) [31]. The DISC 
complex  recruits  pro-caspase  8  through  the  adaptor  protein  Fas-associated  death  domain 
(FADD), activating downstream procaspases like caspase 3 to induce apoptosis [32].  
 
Inhibiting proliferation of tumor cell: The anti-proliferative effect of resveratrol in tumor cells 
has been extensively described [33, 34]. In a wide variety of tumor cells, the growth-inhibitory 
effects of resveratrol were shown to be mediated through cell-cycle arrest. Most of the cell cycle 
is  controlled  by  a  family  of  protein  kinase  complexes  which  constitutes  a  cyclin  dependent 
kinase (cdk) and the corresponding cyclin [31]. Wolter et al. showed the down-regulation of the 
cyclin D1/cdk 4 complex by resveratrol in colon cancer cells [35]. Resveratrol can also induce 
G1 phase arrest by decreasing the protein expression of cyclin D2, E, and cdk 2, 6 through 
inhibiting binding of transcription factors such as nuclear factor-kappa B (NF-κB) and activator 
protein-1  (AP-1).  Resveratrol  was  shown  to  induce  the  translocation  and  expression  of  cdk 
inhibitors, p21 and p27, by up-regulation of transcription factors. Cdk inhibitors inhibit active 
cyclin/cdk complexes and block the G1/S phase transition [31]. Resveratrol can also decrease the 
expression of c-Myc, a cyclin E/cdk 2 activator, preventing the cell from going through G1/S 
phase transition [36].    There are several mechanism reported with regard to S phase arrest by 
resveratrol. Resveratrol can disrupt the dephosphorylation of cdk 1, a key regulator of the cell 
cycle  and  the  progression  through  the  S  phase  [31].  Larrosa  et  al.  reported  that  resveratrol 
induced S-phase arrest and up-regulation of cyclins A, E and B1 in human melanoma cells [37]. 
S phase arrest by resveratrol was also induced by direct inhibition of DNA synthesis through, for 
example,  inhibiting  ribonucleotide  synthase  and  DNA  polymerases  [38].  Liang  et  al. 
demonstrated that resveratrol induced G2 phase arrest through the inhibition of Cdk 7 and Cdc 2 
kinases in colon carcinoma cells [39]. Thus, it seems to be clear that the resveratrol effects on the 
cell-cycle are highly variable [33].  
Another mechanism of anti-proliferative effect of resveratrol was mediated through its role 
as a calorie restriction (CR) mimetic. CR is widely believed to extend the lifespan and protect 
against aging-related diseases including cancer [40]. Accumulating evidence showed that CR 
effect of resveratrol might be associated with increasing silent information regulator 2/sirtuin 1 
(SIRT)  activity  [6].  SIRTs  belong  to  the  class  III  histone/protein  deacetylases,  which  are 
implicated in CR, aging, and inflammation [41]. One key enzyme thought to be activated during 
CR is AMP-activated kinase (AMPK), a sensor of cellular energy levels [42]. Once activated, 
AMPK inhibited 4E-BP1 signaling and mRNA translation via mTOR, leading to inhibition of 
cellular  proliferation.  In  addition,  resveratrol-mediated  AMPK  activation  was  shown  to  be 
caused by inducing the expression of SIRT1 via elevation in the cellular NAD (+)/NADH in Functional Foods in Health and Disease 2013; 3(8):332-343 
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estrogen  receptor-positive  breast  cancer  cells.  These  findings  suggest  that  targeting 
SIRT1/AMPK signaling by resveratrol may have potential therapeutic implications for cancer. 
P53 is a key tumor suppressor protein that has multiple functions which help to prevent 
cancer  development  including  regulation  of  cell  growth  as  well  as  promoting  apoptosis  and 
dampening glycolysis [43]. Tumor cells often mutate or lose p53 to ensure replicative potential. 
Warburg effect is known to be directly caused by the inactivation of p53. P53 can inhibit the 
expression of glucose transporters (GLUT) 1 and 4, and phosphoglycerate mutase (PGM), the 
enzyme that converts 3-phosphoglycerate to 2-phosphoglycerate in glycolysis, while increasing 
the expression of TP53-induced glycolysis and apoptosis regulator (TIGAR) [22]. TIGAR is an 
isoform of PFK2 that inhibits overall PFK activity through lowering the levels of fructose-2, 6-
bisphosphate, an allosteric activator of PFK1, and hence inhibits glycolysis while channeling 
glucose  to  the  PPP  [44].  Again,  PPP  is  one  of  the  critical  pathways  for  macromolecular 
biosynthesis which is needed to supply building blocks for cell replication. There are several 
lines of evidence demonstrating that resveratrol can up-regulate the expression of p53 in various 
cancer  cell  lines  including  breast,  prostate,  and  ovarian  cancers  [45-47].  The  underlying 
mechanism of p53 up-regulation by resveratrol is not clearly understood. Nevertheless, Zhang et 
al. proposed that resveratrol could activate p53 with the help of mitogen-activated protein kinase 
(MAPK), which phosphorylates and acetylates p53 [48].  
 
Angioprevention: anti- metastatic effect through inhibiting inflammation and angiogenesis: 
It is now well established that metabolic syndrome is a risk factor for at least some types of 
cancers  including  breast,  colon,  and  prostate  cancers  [5]. Among  the  involved  pathological 
manifestations are inflammation and endothelial cell dysfunction. Obesity may shift the balance 
toward a pro-angiogenic and pro-inflammatory function, and become a reservoir for dysregulated 
inflammatory cells such as macrophages and T lymphocytes. These inflammatory cells are able 
to  release  cytokines  for tumor promotion  and angiogenesis  [5]. The inflammatory mediators 
include  cytokines  such  as  interleukin  (IL)-1,  6,  8,  and  tissue  necrosis  factor-ʱ  (TNF-ʱ), 
prostaglandins, and nitric oxide [49]. Cyclooxygenase (COX), which catalyzes the conversion of 
arachidonic  acid  to  prostaglandins,  was  shown  to  be  able  to  activate  procarcinogens,  thus, 
making  transgenic  mice  with  an  increased  expression  of  COX-2  highly  susceptible  to 
spontaneous  skin  tumor  formation  [50].  Surh  et  al.  reported  that  COX-2  was  implicated  in 
increased invasiveness as well as metastatic potential of tumor cells [51]. Transcription of COX-
2 is regulated by several transcription factors including NF-κB [31]. NF-κB, one of the most 
important  transcription  factors  regulating  inflammatory  responses,  cellular  proliferation  and 
growth as well as oncogenesis, is known to exist as a heterodimer and sterically blocked by IκB 
[52]. The balance between NF-κB and IκB was considered important to the tumor development 
[53].  
Resveratrol was demonstrated to directly block NF-κB activation in cell type non-specific 
manner [54]. In addition, accumulating evidence proposed several mechanisms underlying the 
NF-κB inhibition by resveratrol. Kundu et al. reported that resveratrol could prevent the activity 
of NF-κB by inhibiting degradation of IκBʱ in oxidative stress-stimulated mouse skin model 
[55]. MAPK phosphatase 5 (MAPK5) is known as a potent inhibitor of cellular inflammatory 
responses because MAPK5 can block the enzymatic activation of MAPK, which is one of the Functional Foods in Health and Disease 2013; 3(8):332-343 
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upstream kinases that regulate the activation of NF-κB, with a high selectivity for p38. It was 
shown that resveratrol could up-regulate MAPK5 and inhibit p38 pathway in prostate cancer cell 
lines [56]. Moreover, resveratrol  can inhibit NF-κB both by blocking the upstream activator 
PKCʴ and by activating the inhibitor SIRT1 [57].  
   Angiogenesis is essential for tumor to survive and metastasize. It is usually required for 
tumor  growth  beyond  a  diameter  1-2  mm  and  stimulated  by,  most  importantly,  vascular 
endothelial  growth  factor  (VEGF)  [58].  Resveratrol  was  shown  to  inhibit  tumor-induced 
neovascularization through inhibiting VEGF expression in various cancer cell lines [59, 60]. The 
anti-angiogenic effect of resveratrol is also through inhibiting other mediators including basic 
fibroblast  growth  factor  (bFGF)  and  matrix  metalloproteinase-2,  9  (MMP-2,  9).  MMPs  are 
endopeptidases  that  cleave  protein  components  of  extracellular  matix  contributing  to  cell 
migration for angiogenesis as well as metastasis [61]. Resveratrol was shown to markedly inhibit 
MMP-9 activity and expression at both protein and mRNA levels in breast cancer cells [62]. In 
this study, resveratrol attenuated PI3K and phosphorylation of AKT and mTOR. In addition, 
resveratrol  inhibited  NF-κB  transcriptional  activity  and  DNA  binding  of  NF-κB  on  MMP-9 
promoter. These results suggest that resveratrol may suppress breast cancer cell invasion through 
the inhibition of MMP-9 involved in PI3K/AKT and NF-κB pathways. Mousa et al. showed that 
resveratrol  could  inhibit  bFGF-induced  angiogenesis  in  the  chick  chorioallantoic  membrane 
model [63].  
Tosetti et al. have shown the capacity of dietary phytochemicals including resveratrol to 
inhibit inflammation and angiogenesis, termed angioprevention [5]. Along with down-regulation 
of NF-κB by resveratrol, a variety of inflammatory cytokines such as IL-1, 6, 8, and TNF-ʱ were 
main targets of resveratrol [33]. Given that MAPK is a crucial component in both signaling 
pathways for inflammatory responses and endothelial cell proliferation, the inhibitory effect of 
resveratrol on MAPK suggests that resveratrol might play an important role in angioprevention 
to prevent tumor metastasis.  
   
CONCLUSIONS: 
Resveratrol  is  widely  considered  to  exhibit  beneficial  health  effects.  Anti-cancer  effects  of 
resveratrol seem to be of particular interest at present, because resveratrol shares most of its 
targets with metabolic reprogramming of tumor cells. Metabolic reprogramming is a reemerging 
issue  in  recent  cancer  biology.  Briefly,  resveratrol  down-regulates  the  increased  glycolytic 
activity of tumor cells  at  multiple levels,  facilitating apoptosis  of tumor cells  and inhibiting 
tumor  cell  proliferation.  Moreover,  resveratrol  might  prevent  metastasis  and  tumor  invasion 
through inhibiting inflammation and angiogenesis.  
Of note, the anti-cancer effects of resveratrol are thought to have cancer selectivity with 
minimal toxicity to normal cells. Low pH condition around tumor cells due to increased lactate 
production  from  enhanced  glycolysis  may  promote  the  pro-oxidant  anti-cancer  activity  of 
resveratrol [30]. It should be pointed out that the IC50 of resveratrol for proliferation inhibition 
was significantly lower for cancer cells as compared to normal cells [64]. The cancer selectivity 
of resveratrol might help to circumvent its limit of low bioavailability. There are several clinical 
trials of resveratrol for testing its efficacy in prevention and treatment of cancer. We should wait 
for their results to find out whether the promising experimental and preclinical data will be Functional Foods in Health and Disease 2013; 3(8):332-343 
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proven in clinical setting.  
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